OneDigital Investment Advisors LLC lifted its position in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 16.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 32,130 shares of the company's stock after buying an additional 4,485 shares during the quarter. OneDigital Investment Advisors LLC's holdings in AstraZeneca were worth $2,105,000 as of its most recent filing with the SEC.
A number of other hedge funds have also recently added to or reduced their stakes in AZN. TD Waterhouse Canada Inc. lifted its holdings in AstraZeneca by 27.1% in the 4th quarter. TD Waterhouse Canada Inc. now owns 15,492 shares of the company's stock worth $1,015,000 after purchasing an additional 3,302 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in AstraZeneca by 149.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 40,740 shares of the company's stock valued at $2,669,000 after purchasing an additional 24,378 shares during the period. MML Investors Services LLC grew its stake in shares of AstraZeneca by 0.4% in the fourth quarter. MML Investors Services LLC now owns 256,610 shares of the company's stock worth $16,813,000 after acquiring an additional 1,005 shares during the last quarter. Norinchukin Bank The increased its holdings in shares of AstraZeneca by 8.5% during the 4th quarter. Norinchukin Bank The now owns 5,630 shares of the company's stock worth $369,000 after purchasing an additional 439 shares during the period. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of AstraZeneca during the fourth quarter valued at about $58,821,000. Institutional investors and hedge funds own 20.35% of the company's stock.
AstraZeneca Price Performance
Shares of AZN traded up $1.35 on Tuesday, hitting $71.28. The company's stock had a trading volume of 4,403,798 shares, compared to its average volume of 5,184,523. The company has a market capitalization of $221.06 billion, a PE ratio of 31.56, a PEG ratio of 1.42 and a beta of 0.49. AstraZeneca PLC has a fifty-two week low of $61.24 and a fifty-two week high of $87.68. The company has a 50 day moving average price of $72.25 and a 200 day moving average price of $70.10. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.93 and a quick ratio of 0.74.
AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.05 EPS for the quarter, missing analysts' consensus estimates of $1.10 by ($0.05). AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. On average, research analysts anticipate that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.
AstraZeneca Increases Dividend
The business also recently announced a semi-annual dividend, which was paid on Monday, March 24th. Shareholders of record on Friday, February 21st were paid a $1.03 dividend. The ex-dividend date was Friday, February 21st. This is an increase from AstraZeneca's previous semi-annual dividend of $0.49. This represents a dividend yield of 2%. AstraZeneca's payout ratio is currently 91.15%.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on AZN shares. BNP Paribas initiated coverage on AstraZeneca in a research note on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price target on the stock. Morgan Stanley started coverage on AstraZeneca in a research report on Wednesday, February 12th. They set an "overweight" rating on the stock. Finally, UBS Group raised AstraZeneca from a "neutral" rating to a "buy" rating in a research report on Thursday, February 13th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $88.00.
Get Our Latest Report on AZN
About AstraZeneca
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Further Reading
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
